10-QPeriod: Q3 FY2008

DEXCOM INC Quarterly Report for Q3 Ended Sep 30, 2008

Filed November 10, 2008For Securities:DXCM

Summary

DexCom, Inc. (DXCM) reported its third-quarter 2008 financial results, highlighting continued revenue growth, albeit with ongoing net losses as the company invests heavily in product development and market expansion. The company's primary focus remains on its SEVEN continuous glucose monitoring system, which is driving increased product revenue. However, the significant investments in research and development, coupled with selling, general, and administrative expenses, have led to substantial operating losses. Financially, DexCom faces challenges related to its substantial accumulated deficit and a reliance on external financing. While cash reserves have decreased significantly compared to the previous year, the company believes its current liquidity is sufficient to fund operations through at least September 2009. A key concern for investors is the lack of widespread third-party reimbursement for its products, which significantly impacts patient adoption and sales potential.

Key Highlights

  • 1Product revenue increased to $1.9 million for the third quarter of 2008, up from $1.2 million in the prior year's comparable period, driven by higher sales volume of the SEVEN system.
  • 2Despite revenue growth, the company reported a net loss of $14.7 million for the third quarter of 2008, an increase from a loss of $11.4 million in the same period of 2007.
  • 3Research and development expenses rose to $5.4 million for the quarter, an increase of $1.7 million year-over-year, reflecting ongoing investment in product enhancement and new development.
  • 4Selling, general, and administrative expenses also increased to $6.7 million from $5.9 million, primarily due to higher salaries and facilities costs.
  • 5Cash and cash equivalents significantly decreased to $4.6 million as of September 30, 2008, from $23.1 million at the end of 2007, indicating substantial cash burn.
  • 6The company continues to face a significant accumulated deficit of $218 million as of September 30, 2008.
  • 7DexCom is actively engaged in patent litigation with Abbott Diabetes Care, Inc., which presents ongoing legal and financial risks.
  • 8The company's SEVEN system does not yet qualify for Medicare reimbursement, and it continues to work on securing coverage from private third-party payors, a critical factor for wider market adoption.

Frequently Asked Questions

DexCom's primary revenue driver is its SEVEN continuous glucose monitoring system. Product revenue for the third quarter of 2008 increased to $1.9 million, up from $1.2 million in the prior year, primarily due to increased sales volume.

DexCom continues to incur significant net losses. For the third quarter of 2008, the net loss was $14.7 million, compared to $11.4 million in the same period of 2007. This is driven by substantial investments in research and development and selling, general, and administrative expenses, which outweigh the revenue generated.

The company's cash and cash equivalents have decreased substantially to $4.6 million as of September 30, 2008, down from $23.1 million at the end of 2007. While DexCom believes its current cash reserves are sufficient to fund operations through at least September 2009, the significant cash burn and accumulated deficit indicate ongoing liquidity challenges. A major concern is the lack of widespread third-party reimbursement, which hinders revenue growth and patient adoption.

Key risks include the limited operating history and potential lack of market acceptance for its products, ongoing significant net losses, substantial debt obligations, dilution from potential conversion of convertible notes, dependence on third-party suppliers, intellectual property disputes (specifically the patent litigation with Abbott Diabetes Care), and the critical need for broad third-party reimbursement for its continuous glucose monitoring systems.